INTRODUCTION
Current systemic therapies for breast cancer, such as chemotherapy and hormonal therapy, are partially effective in killing cancer cells and controlling tumor growth. Yet nearly all patients with metastatic breast cancer, and a quarter of those with early disease, will relapse despite initial response.
In part, this may be due to inherent limitations in existing therapies that were selected for clinical development based on their effects on proliferative and apoptotic pathways, resulting in temporary therapy-induced shrinkage of cell lines, xenografts, and human breast cancers [1] . Accumulating evidence supports the existence of breast cancer stem cells (BCSCs), which are characterized by their capacity to self-renew and divide indefinitely, and their resistance to conventional therapies [2] . BCSC theory predicts that complete eradication of BCSCs is necessary to achieve a cure, but in patients with symptomatic metastatic disease, eliminating the small population of BCSCs would do little in the short term to reduce tumor burden and preserve organ function. Combinations of conventional, tumorshrinking cytotoxics and BCSC-directed therapies have the potential to both treat patient symptoms and prevent future relapses of breast cancer.
We and others have hypothesized that Notch inhibition will result in control of advanced breast cancer through the elimination of BCSCs [3, 4] . Preclinical data indicate that the Notch pathway is dysregulated in a variety of cancers including T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) [5] , breast cancer [6] , colon cancer [7] , and several other cancers. The inappropriate activation of Notch signaling results in signals that stimulate proliferation, restrict differentiation, and prevent apoptosis in cancer cells (recently reviewed in [8] ). In normal tissues, activation of the Notch pathway results in changes in cell fate, including self-renewal of stem cells or differentiation along a particular lineage [9] .
Specific to the breast, the Notch pathway was shown to be involved in the normal development of the mammary gland and in carcinogenesis [10, 11] . Notch and other highly preserved developmental pathways, including Wnt and Hedgehog, have been hypothesized to be central for the maintenance of Author Manuscript Published OnlineFirst on January 22, 2013; DOI: 10.1158/1078-0432.CCR- BCSCs [12] . For example, gene expression analysis of tumorigenic, mammosphere-forming human BCSCs versus non-tumorigenic cells implicated the Notch, Phosphatidylinositol 3-kinase (PI3K), and Hedgehog signaling pathways in regulating BCSC [13, 14] .
MK-0752 is an experimental oral pharmaceutical under development for the treatment of solid tumor malignancies. In vitro, MK-0752 significantly inhibits gamma secretase, an aspartic protease required for activation of the Notch receptor [15] . Cleavage of the Notch receptor by gamma-secretase is required to release the Notch intracellular domain (NICD), which then translocates to the nucleus, turning on genes involved in cell differentiation and proliferation [9, 15] . Thus, gamma secretase inhibition results in a loss of Notch function in cells [16] . MK-0752 has been evaluated in solid tumor malignancies including refractory pediatric CNS tumors and various adult solid tumors [17, 18] . The recommended phase II dose from the pediatric trial was 260 mg/m2/dose once daily using a 3 days on followed by 4 days off schedule [17] . The adult trial saw pharmacodynamic and clinical activity limited to CNS gliomas at a dose of 1800 mg weekly [18] .
We hypothesized based on preclinical data implicating Notch signaling in BCSC, that a combination of cytotoxic chemotherapy to address the proliferating, non-BCSC proportion of the breast tumors, together with a GSI, would result in better disease control than either therapy alone. Since combination chemotherapy and GSI therapy had never been attempted in humans before, we planned a Phase I trial to determine a tolerable dose and schedule. Concurrent with the Phase I trial, we performed human breast tumorgraft studies to evaluate the impact of gamma secretase inhibitors on the BCSC population and the efficacy of combining GSI with docetaxel treatment. Targeted anticancer therapies are best developed in conjunction with biomarkers that can identify patients with a higher chance of benefit from the treatment, and/or measure treatment efficacy. The ideal biomarker for pharmacodynamic evaluation of cancer stem cell therapies would be able to accurately measure the proportion of stem cells within the tumor, so as to select patients with a high proportion of stem cells 7 for treatment, and to determine on pre-and post-therapy specimens whether the proportion of stem cells within the tumor decreased with the therapy. The proof of "stem cell-ness" requires that the cell population exhibit the archetypal stem cell properties of self-renewal and generation of differentiated progeny [19] [20] [21] . These properties are evaluated in vitro by determining the ability of a single cell to generate a differentiated tissue [13] . In breast cancer models, BCSCs can be identified by their ability to form non-adherent mammospheres in serum-free media (MSFE), and to initiate tumors upon retransplantation. Although the MSFE and re-transplantation approaches to stem cell identification are possible to execute in a preclinical setting, these are impractical to carry out in most clinical situations.
Breast cancer stem cells have been characterized by the cell surface marker phenotype (CD44 + /CD24 -/low ) [22] and aldehyde dehydrogenase activity (ALDH + ) [23, 24] , which identifies these assays as potential surrogate biomarkers for BCSC directed therapies in clinical applications. In summary, although previous studies have examined the effect of GSI on BCSCs in vitro and in cell lines, none have translated this work to clinical studies. In the studies reported herein, we performed a Phase I clinical trial to establish a safe and potentially efficacious combination of a GSI in combination with docetaxel chemotherapy in patients with advanced breast cancer. We tested GSI, docetaxel, and combination therapy modeled after the clinical trial regimen on mice bearing human tumorgrafts in order to evaluate the effects of treatment on tumor volume and/or BCSCs as determined 
MATERIALS AND METHODS

Preclinical Studies.
For preclinical evaluation of BCSC inhibitors, the Chang laboratory in collaboration with Michael T. Lewis has developed stable breast cancer-in-mice xenograft models by transplanting human breast cancer tumor biopsies into the mammary gland fat pad of immune deficient mice (herein referred to as tumorgrafts). To evaluate the effectiveness of stem cell targeted agents in altering the tumorigenic BCSC population, the mice are treated with the agents and the tumor subsequently excised for rigorous evaluation in BCSC assays. These BCSC assays include: 1) flow cytometric analysis of BCSC cell-surface markers and aldehyde dehydrogenase activity (CD44 + /CD24
-and ALDH + , respectively); 2) mammosphere forming efficiency (MSFE); and 3) re-transplantation to measure the presence of tumor-initiating cells (TICs).
Preparation of Tumorgrafts.
All animal protocols were reviewed and approved by the Animal Protocol Review Committee at Baylor College of Medicine or The Methodist Hospital Research Institute. Tumorgrafts were initially generated by transplantation of patient breast cancer tumor biopsies or a fragment of surgical specimens into the cleared fat-pad of SCID/Beige mice (Harlan Laboratories, Indiana, IN, USA) as previously described [20, 21, 25] . As previously described, MC1 human tumors were originally derived from a pleural effusion and are estrogen and progesterone receptor negative and HER-2 negative [22, 24] . BCM-2147 breast tumorgrafts were generated by transplantation of estrogen and progesterone Tumors were collected from the mice and dissociated as described [21] with minor changes. Flow cytometry [20] . City, CA, USA). The following adjustable analysis settings were used: automatic threshold (C T ), automatic outlier removal, and relative quantification (RQ) min/max confidence 99%. All data were calibrated to pooled cDNA and each sample was normalized to 18S rRNA endogenous control. At least three independent tissue samples were evaluated per experimental group.
Protein extraction and western blot.
Research. Whole cell lysates were isolated with Cell Signaling Technologies (CST) Lysis Buffer (20 mM TrisCCl (pH 7.5), 150 mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton, 25 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4 and 1 ug/ml leupeptin, using QiagenTM TissueLyser. Twenty micrograms of protein were loaded on 3-8% Nupage Novex Mini Gels (Invitrogen) and transferred to PVDF membrane. Membranes were then blocked with 5% non-fat milk solution in TBS with Tween-20 (0.05%,TBST) at room temperature for 1 hour, followed by 4°C overnight incubation with primary 
Statistical analysis-Preclinical.
Comparison of categorical data i.e. numbers of tumor initiating cells among vehicle-and GSI-treated mice was done by Fischer's exact test or χ2 test. A one-way ANOVA was used for significant differences among treatment groups in mammosphere assays with Bonferroni's multiple comparison post-test for comparison of two specific groups. Generalized estimating equations (GEE) models from longitudinal data analysis were used to model the treatment and time effects on tumor volume. Interactions terms between treatment and time were tested; however, it was not statistically significant. Variables that did not follow a normal distribution were transformed appropriately. All preclinical statistical analyses were performed using STATA (Version 11, College Station, TX, USA). Author Manuscript Published OnlineFirst on January 22, 2013; DOI: 10.1158/1078-0432.CCR- using the 3 days on, four days off schedule was available. Therefore, the Phase I study utilized a regimen of GSI (MK-0752) on days 1-3 in a dose determined by the dose escalation schema, followed by docetaxel on day 8 of each 21 day cycle. Docetaxel was administered in the standard 21 day dosing schedule, as a weekly docetaxel schedule would not allow sufficient time between docetaxel and MK-0752 to avoid the toxicity observed in the mice. Dose level assignment was done by the coordinating statistician (KAG) at the University of Michigan, after subject registration and confirmation of eligibility. patient was required to come off study. Docetaxel dose reduction of 20% was mandated for emergence of abnormal liver function tests, Grade 2 neuropathy, and Grade 3 and 4 non-hematologic toxicities. For Grade 3 or higher neuropathy, the patient was required to come off study. Once a dose of MK-0752 or docetaxel was reduced, it was not re-escalated.
Efficacy monitoring.
Patients were required to have baseline physical examination, x-rays, and CT scans as necessary to assess measurable and evaluable disease. Radiologic imaging and physical examination for tumor response was repeated every odd cycle until the time of disease progression or treatment discontinuation, whichever came first. Response was assessed using RECIST 1.0 criteria. Study patients with tumors amenable to biopsy had optional research core biopsies obtained before beginning study 
without recruitment pauses, as long as patients were treated at a dose consistent with the current safety profile.
DLT was defined on toxicities possibly, probably, or definitely related to the study drug observed during the first cycle (first 21 days) as follows:
1.
Non-hematologic toxicity Grade ≥3 by the NCI CTCAE version 3.0.
2. ANC<1000 for more than 7 days despite use of pegfilgrastim.
3.
Platelet count <25,000 for more than 7 days, or associated with bleeding, or less than 10,000 at any time.
The target rate of acute toxicity for this trial was 20%, and this target rate defined the MTD of Thirty patients were planned for estimation of the dose-toxicity function. During the treatment of the first 18 patients, accrual was limited to a maximum of 3 patients per calendar month in order to allow sufficient time for observation of toxicity. Following the completion of the acute toxicity observation period for the 18th subject, patients were then accrued at the natural rate possible for the three sites, until 30 patients were accrued and treated on protocol.
Final estimates for the probability of dose-limiting toxicity and 95% Bayesian confidence (credible) intervals for each dose level were calculated using Markov Chain Monte Carlo methods for
Research. 
those cases (N = 29) that either completed the acute observation period (first 21-day cycle) without dose-limiting toxicity or that experienced a DLT during that period.
RESULTS
Treatment with GSI reduced the BCSC population in patient-derived breast tumorgrafts.
To evaluate the ability of GSI to target BCSCs, we performed a series of preclinical studies with mice bearing human breast tumorgrafts. Similar to the inclusion criteria for the clinical trial, these tumorgrafts were derived from advanced and/or chemotherapy-resistant breast cancer. MC1 was derived from metastatic breast tumor cells in pleural effusate and is docetaxel sensitive [22, 24, 26] while BCM-2147 was derived from docetaxel-resistant triple negative invasive breast cancer. To retain the characteristics of the original patient tumors, these tumors were maintained by passage in mice and never under cell culture conditions. Maintenance of patient biomarkers and histopathology was confirmed by immunohistochemical analysis, and genetic stability across multiple transplant generations was confirmed by Affymetrix gene expression, Reverse Phase Protein Assay, and Sequenome analysis (manuscript submitted).
Our treatment approach was to target BCSCs with GSI, while reducing tumor bulk with a standard chemotherapy. We carried out short-term studies to determine the immediate effects of GSI treatment on BCSCs (Fig 1) . Mice with MC1 or BCM-2147 tumorgrafts were stratified to equally distribute tumor size amongst two treatment groups and treated as follows: i) the vehicle control group received GSI vehicle at corresponding treatment time points; ii) the GSI group received GSI (100 mg/kg) by oral gavage for 3 days. To allow for turnover of tumor cells in response to treatment in vivo, the tumors were collected 72 hours after the final treatment, dissociated to single cell suspensions for BCSC assays including flow cytometric analysis for BCSC markers, MSFE, and tumor-initiation in mice.
Consistent with decreased BCSCs, primary and secondary MSFE were significantly decreased in GSI-treated tumors compared to vehicle-treated tumors (Fig. 1A) (Fig. 1B) . BCM-2147 does not have a CD44-positive population for evaluation, therefore only ALDH was evaluated by flow cytometry. To determine whether treatment had reduced BCSCs, we retransplanted the MC1 tumor cells from each group into mice and monitored tumor development ( Table   1 ). The vehicle-treated tumor cells regenerated tumors with 50-55% tumor incidence. Importantly, there were no regenerated tumors in the GSI-treated group (P<0.011), indicating GSI reduced tumor cells capable of tumor initiation.
GSI inhibited the Notch pathway.
To ensure that GSI was inhibiting the Notch pathway in our tumorgrafts, we evaluated expression of the Notch intracellular domain (NICD) and downstream targets of the Notch pathway in response to GSI treatment in MC1 and BCM-2147 tumors (Fig 2) . Quantification of western blot data confirmed downregulation of NICD with GSI treatment in MC1 and BCM-2147 tumors (Fig 2A) . In MC1 tumors, Hes1, Hey1, Hes5, and myc were reduced to 40%, 50%, 25%, and 40% respectively, in the GSItreated tumors relative to controls (Fig 2B) . In BCM-2147 tumors, Hes1 and other Notch targets were not significantly decreased in the whole tumor (Fig 2B and data not shown) ; thus, we collected treated tumors and flow sorted for the ALDH+ BCSC population. Hes1 expression was markedly reduced to less than 5% of control within the ALDH+ population, further supporting the role of the Notch pathway in BCSCs. Because the ALDH+ population is less than 2% of the whole tumor, the change in expression was undetectable in the whole tumor. Collectively, these data indicate that GSI inhibited activation of NICD and reduced Notch pathway targets.
Treatment with GSI enhanced efficacy of docetaxel and reduced BCSCs.
To evaluate in a preclinical setting the GSI and docetaxel treatment regimen used in the Phase I clinical trial, mice bearing MC1 or BCM-2147 tumors were stratified by tumor size to treatment groups: docetaxel (10 mg/kg), GSI (100 mg/kg), or a combination of both and compared to animals treated with vehicle alone. The doses were chosen based on toxicity and efficacy in our animal model. Single agent treatment with either GSI or docetaxel delayed MC1 tumor progression, but eventually, after treatment was stopped, tumors reached sizes equivalent to control mice ( Fig 3A) . As expected, treatment with docetaxel did not significantly reduce tumor volume in docetaxel-resistant BCM-2147, while GSI alone and GSI with docetaxel reduced tumor growth compared to vehicle (Fig 3B) . GSI alone also reduced mammosphere forming efficiency (MSFE) compared to vehicle-and docetaxel-treated tumors (Fig 3B) .
The combination of GSI and docetaxel decreased tumor size more than the single agents in both MC1
and BCM-2147 tumors (Fig 3) . Regimens proposed to be used in human patients were used to assess efficacy of treatment. The difference in tumor growth between mice treated with docetaxel alone and combination of GSI and docetaxel at either 3-or 5-day intervals is significant ( Fig 3C; P< 0.01 and 0.05, respectively). GSI alone slows tumor growth significantly compared to control (P<0.03). There was no significant difference between administration of docetaxel 3 days after GSI compared to 5 days after GSI (P<0.09) Administration of docetaxel earlier than 3 days post GSI or concomitant administration of docetaxel and GSI showed significant toxicity in mice, consisting of diarrhea, dehydration and severe weight loss. In summary, GSI treatment reduced BCSC and enhanced the efficacy of docetaxel.
Phase IB Clinical Trial of the GSI, MK-0752, with Docetaxel
The clinical trial was designed with the overall goals of determining a safe and potentially efficacious dose and schedule of combination MK0752 with docetaxel in patients with locally advanced or metastatic breast cancer, and to explore for an effect on BCSCs. At the time of study initiation, MK-0752 was in clinical development for the treatment of Alzheimer's disease and other conditions, and therefore its toxicology and dose limiting toxicities in a non-cancer patient population were known.
Limited single agent Phase I data in cancer patients were available at the time of study initiation. Table 2 , and toxicities and their grades are presented in Table 3 . Dose level 3 was selected for further study based on its tolerability in combination with docetaxel in this schedule.
26/30 participants entered the study with measurable disease by RECIST criteria. However, two of these individuals were not evaluable for response due to DLT in the first cycle that led to a change in treatment prior to re-assessment of disease. Of the 24 participants evaluable for response, we observed 11 PR, 9 SD, and 3 PD (Table 1, supplementary data) . The four individuals with non-measurable disease had evaluable disease in skin, bone, and/or pleura. These efficacy data should be interpreted with caution, as all participants received a known active therapy with docetaxel, and therefore these responses cannot be solely attributed to study drug.
Treatment with MK0752 plus docetaxel reduced BCSCs in some patient tumors after multiple rounds of treatment.
Our approach for the clinical trial was to reduce tumor bulk with docetaxel and concurrently target BCSCs with GSI. Tumor biopsies were optional for participants on study, and were performed most frequently in those individuals with locally advanced tumors for whom surgical management following initial chemotherapy treatment was planned. Biopsies were attempted in 10/30 participants at baseline, and 7/10 of the baseline biopsies contained tissue adequate for the BCSC assays (Supplementary Table 1 ). Repeat biopsies were obtained in 6/30 participants following cycles 1, 3, and at the time of treatment discontinuation or definitive breast surgery. One individual with adequate baseline tissue refused the repeat biopsies.
The BCSC assay results for participants (n=6) who successfully underwent serial repeat biopsies are reported here (Fig 4) . Of these 6 individuals, 4 had PR and 2 had SD with all but one receiving the highest dose level 3 at 600mg (Fig 4B and Supplementary Table 1 ). CD44 baseline with subsequent decrease is consistent with the concept that Notch inhibition would cause BCSCs to transition into a proliferative state that is more susceptible to cytotoxic therapy, and indicates that multiple treatment cycles are necessary to effectively reduce BCSCs. A decrease in CD44   +   /CD24  -,   ALDH   + , and MSFE (Fig 4C, 4D , and 4E) was observed from baseline to end of treatment even within this small subset of patients, consistent with the ability of GSI to reduce BCSCs as seen in our preclinical human breast tumorgraft experiments. Multiple cycles were required to see the cumulative benefits of this treatment regimen in reducing BCSC and tumor burden. identify the patient population that will receive the most benefit from BCSC-targeted therapies.
DISCUSSION
Our data indicate that using traditional chemotherapy to reduce the tumor bulk in combination with BCSC-targeted therapy is a viable treatment strategy [3, 6] . antibody reduce MSFE in DCIS [3, 11] . In UM-PE13 metastatic breast tumorgraft from pleural effusate, an antibody targeting the Notch ligand, Dll4 (delta-like ligand) in combination with high dose paclitaxel reduces cancer stem cell frequency [27] . Notch inhibition reduces BCSC capacity of MCF7 and MDA-MB-231 cell lines [28] . Finally, the data presented here provide robust collaborative evidence that pharmacological inhibition of Notch signaling in both primary human and clinical samples reduces Table 1 ). Pharmacodynamic studies of tumor biopsies in a subset of participants suggested an effect of combined therapy on the tumor stem cell component in the breast tumors.
Where do we go from here? At the current time, patients who achieve excellent tumor regressions with chemotherapy in the metastatic setting are often continued on the chemotherapy, with all of its inherent toxicities, until the chemotherapy fails to control their disease any longer. Indeed, a recent meta-analysis found that longer treatment results in significantly better progression free survival, and marginally better overall survival [29] . Alternatively, patients and/or their doctors may advocate for a chemotherapy "holiday" to avoid the toxicity of therapy for some number of weeks or months before their disease progresses again. If stem cell targeted therapies are effective in reducing the tumor initiating cell population, then the addition of such therapies to standard chemotherapy has the potential to delay or prevent disease progression after chemotherapy is stopped, with low toxicity. This hypothesis requires further testing in the clinic in a randomized clinical trial. We propose that a randomized Phase II trial of gamma secretase inhibitors in combination with docetaxel, to include both efficacy and pharmacodynamic endpoints, is warranted to test this hypothesis.
TABLES
